The discovery of cell-free fetal DNA in maternal plasma in 1997 has catalyzed the development of noninvasive prenatal diagnosis (1 ) . Fetal DNA represents on average approximately 15% of the total circulating DNA in maternal plasma. The advent of massively parallel sequencing has made possible the analysis of circulating fetal DNA with unprecedented precision.
In 2010, Lo et al. demonstrated that a fetal genomewide genetic map could be assembled by using a combination of DNA-sequencing data from maternal plasma and genetic maps of the parents (2 ) . The latter data include a genotype map of the father and a haplotype-resolved genotype map of the mother. In this approach, the resolution of the deduced fetal genomic map is governed by the resolutions of the parental genetic maps. This approach was used to create a genomewide map of single-nucleotide polymorphism (SNP) alleles that the fetus had inherited from the father but that were absent in the mother's genome (Fig.  1A) . The focus was then shifted to the maternally inherited half of the fetal genome and the SNP alleles that were heterozygous in the mother and homozygous in the father (Fig. 1B) . These heterozygous SNPs would form 2 haplotypes within the mother's genome and on a pair of homologous chromosomes. Analyzing DNAsequencing data of the maternal plasma allowed comparisons of the relative dosages of these haplotypes in maternal plasma. One could then deduce which haplotypes had been passed on to the fetus, an approach termed "relative haplotype dosage analysis." The maternal inheritance of the fetus was resolved as a series of Ͼ3000 haplotype blocks across the entire genome, and the approach was demonstrated to be useful for the noninvasive prenatal diagnosis of monogenic diseases such as ␤-thalassemia (2 ).
In this proof-of-concept study, Lo et al. opted to construct the maternal haplotype map by using fetal genotype information obtained from a chorionic villus sample, but the maternal haplotype could also have been deduced with samples from other members of the mother's family. Similar end points would have been obtained aside from the dozens of haplotype blocks of the total of Ͼ3000 in which meiotic recombination had taken place in the passage of the genetic information from the mother to the fetus. demonstrated the ability to construct a fetal genomic map by combining maternal plasma DNA-sequencing data, paternal genotype information, and maternal haplotype information. In addition, they described several additional developments. First, they sequenced the maternal plasma DNA to a depth of 78-fold haploid genome coverage (3 ), compared with the 65-fold haploid coverage previously reported (2 ) . Second, the number of parental heterozygous SNP sites analyzed was increased by 10-fold (3 ) compared with the earlier study (2 ) . Third, the maternal haplotype was deduced with a direct sequencing-based approach. Fourth, they explored the analysis of maternal plasma DNAsequencing data for detecting fetal de novo mutations and identified 2.5 ϫ 10 7 candidate de novo mutations. Compared with the 44 actual fetal de novo mutations identified by sequencing cord blood of the baby at delivery, only 39 of the candidate mutations deduced from the maternal plasma data were proved true. The sensitivity of their approach was thus 88.6%; however, the positive predictive value of the method was very low because of the extremely large number of falsepositive results.
An overall analysis of the points described above and the data reported by Kitzman et al. demonstrates that the fetal-genome sequencing approach proposed by Lo et al. is scalable and robust, even when it is pushed to a greater sequencing depth and higher resolution. The concept of detecting fetal de novo mutations is interesting, although the specificity and sensitivity would require substantial improvement before the clinical applications could be investigated. Further advances in sequencing technology to allow greater depths of sequencing at reduced costs and with greater accuracy would facilitate such developments.
There remains one group of genomic regions that both Kitzman et al. and Lo et al. did not explore, namely regions where the father and mother of the fetus are both heterozygous. These regions are particularly critical for prenatal diagnosis in families with consanguineous marriage or for diseases in which there is a strong founder effect. In both of these scenarios, the father and mother would be expected to exhibit similarities in the haplotype structure of the genomic regions linked to the disease-causing gene. Theoretically, the fetal genomic map of such regions could be resolved if the haplotypes of both the father and the mother were known. This concept has recently been demonstrated for the ␤-globin gene region for noninvasive prenatal diagnosis of ␤-thalassemia (4 ).
An even more recent report by Fan et al. describes the third attempt at constructing a fetal genomic map noninvasively from maternal plasma DNA-sequencing data (5 ). The depth of sequencing performed by this group was lower than that described in the 2 earlier reports (2, 3 ) . Indeed, the resolution of the deduced fetal genomic map is only approximately 80% of that reported in 2010 ( Although the data of Lo et al. and Kitzman et al. have clearly demonstrated that a fetal genomewide genetic map of any resolution can be constructed with maternal plasma DNA-sequencing data and parental genetic information, such an approach will likely remain expensive for the next few years. Furthermore, many challenges can be envisioned with the application of noninvasive genomewide scanning of mutations within the genomes of fetuses, particularly in ensuring that adequate and appropriate prenatal counseling is available for pregnant women. Careful consideration should be given to the medical, social, legal, and ethical issues regarding the spectrum of genetic disorders to be evaluated in such an exercise. In this regard, a potentially more attractive approach would be to use targeted sequencing (4 ) to focus specifically on selected regions of the human genome for the genetic diseases prevalent in a particular population. This approach has the potential to reduce the cost of implementing such a procedure clinically and to allow counseling of pregnant women for prenatal testing of a carefully selected repertoire of genetic diseases. Targeted sequencing approaches might also be useful for detecting fetal de novo mutations at selected mutational hot spots of particular clinical importance. It is thus a priority to investigate the robustness of performing fetal genomic mapping with data generated by targeted sequencing.
Therefore, it is a very exciting time in the field of noninvasive prenatal diagnosis. With the recent successful implementation of circulating fetal DNA anal- ysis for noninvasive aneuploidy detection, the attention of the field is expected to turn in the near future to monogenic diseases and fetal genome scanning. With due attention paid to the social, ethical, and legal aspects of this field, as well as to the technological issues for improving sensitivity and specificity, one would expect developments in these areas to make prenatal testing safer for the fetus and less stressful for mothers.
